Lorus Therapeutics Inc. · Toronto, ON Canada ·(NYSE Alternext: LRP)(Toronto: LOR)
Company Description
View Lorus Therapeutics Inc. Locations On A US Map
This link will open in a new window
Lorus Therapeutics isn't talking nonsense, they're talking antisense. The biotechnology firm is developing cancer drugs using antisense technology, which prevents cells from producing disease-causing proteins and may cause fewer side effects than traditional chemotherapies. It is testing its lead candidate in this area, LOR-2040, as a treatment for various blood cancers and solid tumors. Lorus is working in other areas of cancer research as well, developing some traditional therapies, as well as immunotherapies, which stimulate the body's immune system to fight cancer. The company licensed its Virulizin immunotherapy, a potential treatment for pancreatic cancer, to a subsidiary of Zoticon Bioventures in 2008. To read the full description, subscribe now.
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!
Lorus Therapeutics Inc. Executives
9 executives listed for Lorus Therapeutics Inc.'s Toronto, ON location.
| Title | Name & Bio | Contact |
| Chairman | Dennis Burger | Network |
| Director, President and CEO | Aiping Young | Network |
| Director Finance and Acting CFO | Elizabeth Williams | Network |
Competition
Competitive Landscape for Lorus Therapeutics Inc.
Demand often depends on the income of consumers or the profitability of business customers, because many technology products and services are expensive. The profitability of individual companies is driven by their ability to develop and market new products. Large companies often have advantages in access to capital and marketing. Small companies can compete successfully if they have expertise in a particular field of knowledge. The industry is capital-intensive: average annual revenue per worker is nearly $300,000. To read the full description, subscribe now.Top Lorus Therapeutics Inc. Competitors
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!
